SPECTREM Phase 3b Clinical Trial Results Through Week 16: Guselkumab Efficacy and Safety for the Treatment of Low Body Surface Area, Moderate Psoriasis With High-Impact Site Involvement

By afschroeder • August 29, 2025

Stein Gold L, Gottlieb AB, Armstrong AW, Alkousakis T, Bissonnette R, Langley RG, Krueger J, Papp K, Choi O, Rowland K, Chan D, Jeyarajah J, Park-Wyllie L, Gao LL, Gordon KB, Merola JF, Lebwohl MG, Strober B. SPECTREM Phase 3b Clinical Trial Results Through Week 16: Guselkumab Efficacy and Safety for the Treatment of Low Body Surface Area, Moderate Psoriasis With High-Impact Site Involvement. Br J Dermatol. 2025 Aug 28:ljaf327. doi: 10.1093/bjd/ljaf327. Epub ahead of print. PMID: 40875818.

Tags: Dermatology, Publications

Complete genomes of the hydrogenotrophic methanogen species -Methanospirillum stamsii Pt1 and Methanospirillum lacunae Ki8-1

Humm E, Chettiyar R, Rubbi L, Del Vecchio G, Pellegrini M, Ha SM, Gunsalus RP. Complete genomes of the hydrogenotrophic methanogen species-Methanospirillum stamsii Pt1 and Methanospirillum lacunae Ki8-1.[...]

A Nationwide Survey of Dermatology Faculty and Mentors on Their Advice for the Dermatology Match Process

D'Amiano AJ, Rohr B, Glick B, Hogeling M, Keller M, Sunshine J. A Nationwide Survey of Dermatology Faculty and Mentors on Their Advice for the[...]

Anti-p200 pemphigoid

Kasperkiewicz M, Pigors M, Holtsche MM, Goletz S, Schmidt E. Anti-p200 pemphigoid. Br J Dermatol. 2025 Aug 25:ljaf324. doi: 10.1093/bjd/ljaf324. Epub ahead of print. PMID:[...]